Elys Game Technology, Corp.

Elys Game Technology, Corp. (NASDAQ: ELYS) is a growing, technologically advanced Sports Betting and i-Gaming full-service provider in the regulated B2B and B2C markets. It focuses on delivering outcomes for casino and leisure gaming operators in Europe, North America, and worldwide through retail and digital solutions.

Key Highlights

• The company reported a 37.25% increase in revenues to USD 33.88 million during 9MFY21 (ended September 30, 2021) compared to USD 24.68 million during 9MFY20.
• Due to increasing operational expenditures such as personnel costs, professional fees, and IT related costs, ELYS witnessed an increase in operating losses to USD 6.43 million during 9MFY21 vs. USD 1.51 million during 9MFY20.
• The company is operating at a ROE and net margins of -14.3% and -43.8% in Q3FY21.
• On November 11, 2021, ELYS and Atlantic City's Ocean Casino Resort announced a collaboration that would begin on March 1, 2022. USBookmaking, a subsidiary of ELYS, will supply Ocean's trade management services and eventual retail solution, subject to regulatory approval from New Jersey's gambling regulators.
• The stock is currently trading below its critical short-term (50-day) and long-term (200-day) DMA support levels, with the RSI Index at 27.72.
• Stock is leaning towards the lower band of the 52-week range of USD 1.40 to USD 8.28.
• ELYS stock price has declined 32.37% and 45.61% in the past six and nine months, respectively.

Technical Price Chart (as of November 23, 2021). Analysis by Kalkine

Conclusion: Considering the uncertain outlook, high operating losses, doubtful positive bottomline results in the near future, and technical indicators, we recommend an "Avoid" rating on the stock at the current price of USD 3.28, down 1.80% as of November 23, 2021, at 2:20 PM ET.

*The reference data in this report has been partly sourced from REFINITIV.

BIOLASE, Inc.

BIOLASE, Inc. (NASDAQ: BIOL) is a major manufacturer of innovative dental laser equipment. The company creates, manufactures, promotes, and distributes laser systems that assist dental professionals and their patients.

Key Highlights

• The company reported a 87.80% increase in revenues to USD 26.78 million during 9MFY21 (ended September 30, 2021) compared to USD 14.26 million during 9MFY20.
• Due to increasing operational expenditures and loss on patent litigation settlement, BIOL witnessed an increase in net losses to USD 10.88 million during 9MFY21 from USD 10.69 million during 9MFY20.
• The company is operating at a ROE and net margins of -10.3% and -34.4% in Q3FY21.
• On November 17, 2021, BIOL asks stockholders to vote in favour of a reverse stock split adjustment (without reducing the authorised number of shares of common stock).
• The stock is currently trading below its critical short-term (50-day) and long-term (200-day) DMA support levels, with the RSI Index at 21.61.
• Stock is leaning towards the lower band of the 52-week range of USD 0.27 to USD 1.51.
• BIOL stock price has declined 37.47% and 56.52% in the past six and nine months, respectively.

Technical Price Chart (as of November 23, 2021). Analysis by Kalkine

Conclusion: Considering the uncertain outlook, doubtful positive bottomline results in the near future, and technical indicators, we recommend an "Avoid" rating on the stock at the current price of USD 0.4211, down 4.53% as of November 23, 2021, at 2:27 PM ET.

*The reference data in this report has been partly sourced from REFINITIV.